On July 1, 2026, women's pelvic-health company Materna Medical announced the successful close of a $5 million "B3" financing round, led by InnovaHealth Partners, Wavemaker360 Health, and Band of Angels with continued support from existing backers. The San Carlos, California-based OBGYN platform company framed the raise as the fuel for "a pivotal year of clinical, commercial, and operational advancement" — most notably completing the readout of its EASE pivotal trial and preparing to launch the Ellora Obstetrical System.

Why It Matters

Postpartum pelvic-floor injury is one of the most direct — and most neglected — pipelines into long-term sexual dysfunction, yet almost no medical device intervenes at the moment of delivery. Materna's Ellora is a rare attempt to prevent that trauma rather than rehab it afterward, and the already-active reimbursement code signals payers may treat it as covered care rather than elective wellness. Meanwhile Milli sits in the same painful-sex category that brands like Ohnut and vaginal-health players have struggled to scale through retail. For investors watching femtech's post-Elvie shakeout, a lean $5M bridge tied to a randomized trial and a live billing code is a template for how hardware-heavy women's-health startups survive a tight funding environment.

Materna's relevance to the sexual-wellness beat runs through its flagship consumer product, Milli — a vaginal dilator engineered to expand in 1-millimeter increments to help patients suffering from vaginismus and related painful sex (dyspareunia). Milli first launched as a wellness trainer in 2019 and received FDA clearance in 2023 to be sold over the counter, positioning it at the intersection of medical device and intimate-wellness retail. The new capital funds expanded Milli channel access alongside the company's second act.

That second act is Ellora, an investigational device used during labor to reduce pelvic floor muscle injury during vaginal delivery in first-time mothers — the kind of birth trauma that is a leading, under-discussed driver of long-term incontinence, prolapse, and sexual dysfunction. Ellora is being studied in the EASE trial, a large randomized controlled trial running across 20 major U.S. hospitals. Materna said its first-in-class reimbursement code is now active, an unusually early insurance milestone that de-risks the eventual commercial launch.

CEO Tracy MacNeal and board chair Dr. Ariella P. Golomb both framed the round as a gateway to the Ellora launch, with proceeds also earmarked for building out commercial manufacturing and market-access strategy. It's a modest raise by femtech standards, but a targeted one: this is bridge capital to carry a device with an active reimbursement pathway across the finish line rather than a splashy growth round.

Sources

Update — 2026-07-03

Initial entry — story first created.